Trials / Withdrawn
WithdrawnNCT05705700
Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
Biomarker Study Targeting Abiraterone Metabolites and Polymporphisms in Men With PSA Progression on Abiraterone for the Treatment of Castration Resistant or Castration Sensitive Prostate Cancer (The Bio-STAMP Study)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, Phase II randomized biomarker-based therapeutic study in metastatic prostate cancer experiencing prostate specific antigen (PSA) only progression (without visceral, bone or lymph node progression) while on abiraterone therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dutasteride | High dose Dutasteride (3.5 mg daily) as add-on therapy at time of PSA progression |
| DRUG | Abiraterone | 1000 mg PO daily |
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2030-01-01
- Completion
- 2030-01-01
- First posted
- 2023-01-31
- Last updated
- 2023-02-27
Source: ClinicalTrials.gov record NCT05705700. Inclusion in this directory is not an endorsement.